CO6602170A2 - Composiciones y metodos para la administracion no toxica de antiprogestinas - Google Patents
Composiciones y metodos para la administracion no toxica de antiprogestinasInfo
- Publication number
- CO6602170A2 CO6602170A2 CO12163077A CO12163077A CO6602170A2 CO 6602170 A2 CO6602170 A2 CO 6602170A2 CO 12163077 A CO12163077 A CO 12163077A CO 12163077 A CO12163077 A CO 12163077A CO 6602170 A2 CO6602170 A2 CO 6602170A2
- Authority
- CO
- Colombia
- Prior art keywords
- subsection
- antiprogestins
- compositions
- methods
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se encuentra dirigida a moduladores de los receptores de la progesterona 19-noresteroide con disminución de la toxicidad hepática. Específicamente nuevos esteroides que producen actividad antiprogestacional potente con una actividad antiglucocorticoide mínima con la siguiente fórmula:Espero con esto haber dado cabal cumplimiento a lo solicitado por ese despacho y de conformidad con lo indicado en los artículos 3°, inciso 3, 35 inciso 2 y 59 inciso 2 del CCA, al analizar este memorial, atentamente ruego se traten todas las cuestiones planteadas con motivo del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31626310P | 2010-03-22 | 2010-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6602170A2 true CO6602170A2 (es) | 2013-01-18 |
Family
ID=44343114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12163077A CO6602170A2 (es) | 2010-03-22 | 2012-09-20 | Composiciones y metodos para la administracion no toxica de antiprogestinas |
Country Status (24)
Country | Link |
---|---|
US (3) | US20130018027A1 (es) |
EP (2) | EP3865502A1 (es) |
JP (4) | JP5894143B2 (es) |
KR (2) | KR20130009990A (es) |
CN (3) | CN107260745A (es) |
AR (1) | AR080692A1 (es) |
AU (4) | AU2010348967C1 (es) |
BR (2) | BR112012023281A2 (es) |
CA (1) | CA2793712A1 (es) |
CL (1) | CL2012002544A1 (es) |
CO (1) | CO6602170A2 (es) |
CR (1) | CR20120514A (es) |
EA (1) | EA023743B1 (es) |
EC (1) | ECSP12012226A (es) |
IL (2) | IL221820B (es) |
MX (1) | MX2012010327A (es) |
MY (1) | MY164622A (es) |
NI (2) | NI201200142A (es) |
NZ (1) | NZ602525A (es) |
SG (3) | SG183924A1 (es) |
TW (1) | TWI581797B (es) |
UA (1) | UA110030C2 (es) |
WO (1) | WO2011119194A1 (es) |
ZA (1) | ZA201207688B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015171319A1 (en) * | 2014-05-05 | 2015-11-12 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
KR20170084086A (ko) | 2014-11-17 | 2017-07-19 | 아르노 테라퓨틱스 인코포레이티드 | 오나프리스톤 연장-방출 조성물 및 방법 |
CA2998924A1 (en) | 2015-09-25 | 2017-03-30 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
CA3015781C (en) * | 2016-02-24 | 2024-04-23 | Eastern Virginia Medical School | An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension |
US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
DE3461090D1 (en) | 1983-02-18 | 1986-12-04 | Schering Ag | 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them |
US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
JPH0830004B2 (ja) | 1983-11-14 | 1996-03-27 | コロンビア ラボラトリーズ インコーポレイテッド | 生物接着性組成物およびそれにより治療する方法 |
DE3347126A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3506785A1 (de) | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
FR2598421B1 (fr) * | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
US5446178A (en) | 1987-03-18 | 1995-08-29 | Schering Aktiengesellschaft | Process for preparing 19,11β-bridged steroids |
DE3866410D1 (de) | 1987-04-24 | 1992-01-09 | Akzo Nv | 11-arylestranderivate und 11-arylpregnanderivate. |
ATE85342T1 (de) | 1987-12-12 | 1993-02-15 | Akzo Nv | 11-arylsteroid-derivate. |
DE3820948A1 (de) | 1988-06-16 | 1989-12-21 | Schering Ag | 10ss, 11ss-ueberbrueckte steroide |
US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
DE3822770A1 (de) | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
DE3832303A1 (de) | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
DE3917274A1 (de) | 1989-05-24 | 1990-11-29 | Schering Ag | 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3921059A1 (de) | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
DE4042007A1 (de) | 1990-12-22 | 1992-06-25 | Schering Ag | 6,7-modifizierte-11(beta)-aryl-4-estrene |
US5407928A (en) | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
DE4038128A1 (de) | 1990-11-27 | 1992-06-04 | Schering Ag | 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
JPH0735335B2 (ja) * | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
ZA929315B (en) | 1991-12-20 | 1993-05-24 | Akzo Nv | 17-spirofuran-3'-ylidene steroids. |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
DE4216004B4 (de) | 1992-05-12 | 2008-03-27 | Bayer Schering Pharma Akiengesellschaft | Verwendung kompetitiver Progesteronantagonisten |
DE4216003A1 (de) | 1992-05-12 | 1993-11-18 | Schering Ag | Dissoziierte kompetitive Progesteronantagonisten |
BR9306661A (pt) | 1992-07-01 | 1998-12-08 | Ortho Pharma Corp | 1-arilsulfonil arilcarbonil E 1-arilfosfonil-3-fenil 1,4,5,6-tetra-hidropidazinas |
US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE4434488A1 (de) | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US5576310A (en) | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
US5688810A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
AU710139B2 (en) * | 1996-05-01 | 1999-09-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | 21-substituted progesterone derivatives as new antiprogestational agents |
US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
WO1998008471A1 (en) * | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
US5753655A (en) | 1996-10-10 | 1998-05-19 | Ortho Pharmaceutical Corporation | 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation |
DE19652408C2 (de) | 1996-12-06 | 2002-04-18 | Schering Ag | Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
DE19809845A1 (de) | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
US6172052B1 (en) * | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6740645B1 (en) * | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
UA74168C2 (uk) * | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
US6476079B1 (en) * | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
MXPA03002954A (es) * | 2000-10-18 | 2003-08-07 | Schering Ag | Uso de antiprogestinas para profilaxis y tratamiento de enfermedades dependientes de las hormonas. |
CN1210079C (zh) * | 2001-04-25 | 2005-07-13 | 上海市计划生育科学研究所 | ***环制剂及其应用 |
CA2573266C (en) * | 2004-07-09 | 2011-11-08 | The Population Council, Inc. | Sustained release compositions containing progesterone receptor modulators |
CN1846703A (zh) * | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮***给药制剂及其组成和制备方法 |
CA2684450C (en) * | 2007-04-20 | 2017-05-30 | Preglem S.A. | Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding |
US20110208118A1 (en) * | 2007-09-20 | 2011-08-25 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and related disorders by mifepristone |
US8299050B2 (en) * | 2008-01-29 | 2012-10-30 | Laboratoire Hra-Pharma | Method for treating uterine fibroids |
-
2010
- 2010-12-23 US US13/636,119 patent/US20130018027A1/en not_active Abandoned
- 2010-12-23 CN CN201710457367.XA patent/CN107260745A/zh active Pending
- 2010-12-23 CN CN201710457607.6A patent/CN107260746A/zh active Pending
- 2010-12-23 KR KR1020127027413A patent/KR20130009990A/ko active Application Filing
- 2010-12-23 AU AU2010348967A patent/AU2010348967C1/en not_active Ceased
- 2010-12-23 JP JP2013501240A patent/JP5894143B2/ja not_active Expired - Fee Related
- 2010-12-23 BR BR112012023281A patent/BR112012023281A2/pt not_active IP Right Cessation
- 2010-12-23 MY MYPI2012004016A patent/MY164622A/en unknown
- 2010-12-23 SG SG2012065801A patent/SG183924A1/en unknown
- 2010-12-23 UA UAA201212075A patent/UA110030C2/uk unknown
- 2010-12-23 SG SG10201504913UA patent/SG10201504913UA/en unknown
- 2010-12-23 KR KR1020187026211A patent/KR102166867B1/ko active IP Right Grant
- 2010-12-23 CN CN2010800669434A patent/CN102906103A/zh active Pending
- 2010-12-23 CA CA2793712A patent/CA2793712A1/en not_active Abandoned
- 2010-12-23 EP EP21167932.9A patent/EP3865502A1/en not_active Withdrawn
- 2010-12-23 WO PCT/US2010/062068 patent/WO2011119194A1/en active Application Filing
- 2010-12-23 EP EP10807575A patent/EP2550288A1/en not_active Ceased
- 2010-12-23 NZ NZ602525A patent/NZ602525A/en not_active IP Right Cessation
- 2010-12-23 MX MX2012010327A patent/MX2012010327A/es unknown
-
2011
- 2011-03-11 TW TW100108248A patent/TWI581797B/zh not_active IP Right Cessation
- 2011-03-18 AR ARP110100899A patent/AR080692A1/es unknown
- 2011-09-08 BR BR112013015509A patent/BR112013015509A2/pt not_active IP Right Cessation
- 2011-09-08 EA EA201390959A patent/EA023743B1/ru not_active IP Right Cessation
- 2011-09-08 SG SG10201510568WA patent/SG10201510568WA/en unknown
-
2012
- 2012-09-06 IL IL221820A patent/IL221820B/en active IP Right Grant
- 2012-09-13 CL CL2012002544A patent/CL2012002544A1/es unknown
- 2012-09-20 NI NI201200142A patent/NI201200142A/es unknown
- 2012-09-20 CO CO12163077A patent/CO6602170A2/es not_active Application Discontinuation
- 2012-10-05 EC ECSP12012226 patent/ECSP12012226A/es unknown
- 2012-10-11 CR CR20120514A patent/CR20120514A/es not_active Application Discontinuation
- 2012-10-12 ZA ZA2012/07688A patent/ZA201207688B/en unknown
-
2013
- 2013-06-21 NI NI201300059A patent/NI201300059A/es unknown
-
2015
- 2015-03-20 US US14/664,518 patent/US20150203526A1/en not_active Abandoned
- 2015-10-13 JP JP2015201752A patent/JP2016029083A/ja not_active Withdrawn
-
2016
- 2016-01-29 AU AU2016200575A patent/AU2016200575B2/en not_active Ceased
-
2017
- 2017-10-27 AU AU2017251837A patent/AU2017251837B2/en not_active Ceased
- 2017-11-06 JP JP2017213755A patent/JP2018016655A/ja not_active Withdrawn
- 2017-11-15 IL IL255679A patent/IL255679A/en unknown
-
2018
- 2018-05-14 US US15/978,988 patent/US20190127413A1/en not_active Abandoned
-
2019
- 2019-05-09 JP JP2019088915A patent/JP2019123756A/ja not_active Withdrawn
-
2020
- 2020-01-02 AU AU2020200027A patent/AU2020200027A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6602170A2 (es) | Composiciones y metodos para la administracion no toxica de antiprogestinas | |
CL2016000060A1 (es) | Derivados piperidinil indol y su uso como inhibidores factor de complemento b. | |
GT201500324A (es) | Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x | |
CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
NI201700135A (es) | Derivados de ciclohexano sustituido con amido | |
CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
CO7240407A2 (es) | Formas cristalinas de un modulador del receptor androgénico | |
DOP2015000202A (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
CR20160099A (es) | Formulación de inhibidores de la syk | |
NZ712350A (en) | Abiraterone acetate formulation | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
CL2015002334A1 (es) | Modificador del sabor dulce | |
CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
CR11826A (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
BR112016002459A8 (pt) | Derivados de benzimidazolil-metil ureia como agonistas receptores de alx | |
CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
UY31973A (es) | Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c | |
BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
DOP2017000244A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
HN2011002578A (es) | Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide. | |
MX2016005142A (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |